TScan Therapeutics, Inc.
TCRX· Nasdaq
TCRXTScan Therapeutics, Inc.
Filed Aug 10, 2022 · 10-Q · 41 days after period end · 0000950170-22-016263
| Metric | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|
| Revenue | $4.06M | $2.85M | — |
| Net Income | -$15.10M | -$10.67M | -$5.61M |
| EPS Diluted | -$0.63 | -$7.69 | -$6.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 10, 2022 · 41 d after period end
